Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PPARA | Q07869 | 6/20 | 0.51 |
| ▸ | PPARG | P37231 | 5/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 6/20 | 0.46 |
| ▸ | CTSK | P43235 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748989 | 1.00 | ACE (0.53) | ACEMAPTSMN1; SMN2PPARAPPARG | |
| SCHEMBL23544337 | 0.90 | MAPT (0.52) | ACEMAPTSMN1; SMN2PPARAPPARG | |
| SCHEMBL31019689 | 0.89 | MAPT (0.51) | ACEMAPTSMN1; SMN2PPARAPPARG | |
| SCHEMBL27203736 | 0.89 | ACE (0.52) | ACEMAPTSMN1; SMN2PPARAPPARG | |
| SCHEMBL5153113 | 0.89 | ACE (0.52) | ACEPPARAPPARGSCN9AITGB3 | |
| SCHEMBL7859254 | 0.89 | ACE (0.52) | ACEPPARAPPARGSCN9AITGB3 | |
| SCHEMBL27207410 | 0.89 | ACE (0.52) | ACEMAPTSMN1; SMN2PPARAPPARG | |
| SCHEMBL7859251 | 0.89 | ACE (0.52) | ACEPPARAPPARGSCN9AITGB3 | |
| SCHEMBL12737917 | 0.88 | PPARA (0.51) | ACEMAPTSMN1; SMN2PPARAPPARG | |
| SCHEMBL2796961 | 0.88 | PPARA (0.51) | ACEMAPTSMN1; SMN2PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968548-B2 | Agonist or antgonist and binders and inversion of agonist; use in the treatment of metabolic, immune, infection-related and melanocortin receptor mediated disorders including specifically treatment of obesity and related conditions | PALATIN TECHNOLOGIES, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7834017-B2 | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents | PALATIN TECHNOLOGIES, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| WO-2010091164-A1 | INHIBITORS OF GLUCOSYLCERAMIDE SYNTHASE | EXELIXIS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-7727990-B2 | Melanocortin receptor-specific piperazine and keto-piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7727991-B2 | Substituted melanocortin receptor-specific single acyl piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1922072-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | Palatin Technologies, Inc. (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1919479-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE AND KETO-PIPERAZINE COMPOUNDS | Palatin Technologies, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| US-20080070921-A1 | Diamine-Containing, Tetra-Substituted Piperazine Compounds Having Identical 1- and 4-Substituents | PALATIN TECHNOLOGIES, INC. (US) | 2008-03-20 | — | — | US | disclosed |
| WO-2008017852-A1 | DIAMINE-CONTAINING, TETRA- SUBSTITUTED PIPERAZINE COMPOUNDS AS MELANOCORTIN RECEPTOR MODULATORS | PALATIN TECHNOLOGIES, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007021990-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021991-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE AND KETO-PIPERAZINE COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20060287330-A1 | Substituted Melanocortin Receptor-Specific Single Acyl Piperazine Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-20060287331-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-20060287332-A1 | Melanocortin Receptor-Specific Piperazine and Keto-Piperazine Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070921-A1 | Diamine-Containing, Tetra-Substituted Piperazine Compounds Having Identical 1- and 4-Substituents | NPY1R, MC5R, MC4R | ACE 3623/4885MAPT 3963/4885SMN1; SMN2 1190/4885 |
| US-20060287332-A1 | Melanocortin Receptor-Specific Piperazine and Keto-Piperazine Compounds | MC4R, MC5R, MC1R | ACE 4330/4885MAPT 2693/4885SMN1; SMN2 4207/4885 |
| US-20060287330-A1 | Substituted Melanocortin Receptor-Specific Single Acyl Piperazine Compounds | MC4R, MC5R, MC3R | ACE 4337/4885MAPT 3820/4885SMN1; SMN2 4533/4885 |
| US-20060287331-A1 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE COMPOUNDS WITH DIAMINE GROUPS | MC4R, MC1R, MC5R | ACE 3994/4885MAPT 2776/4885SMN1; SMN2 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.